Yonsei University: Hepatitis B, Chronic trials
The registry lists 15 Hepatitis B, Chronic studies with Yonsei University as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 3 1Phase 4 8No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- The Establishment of Korean Hepatitis B Patients CohortRecruitingNCT04139850
- Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 DiabetesStatus unknownNCT04584242Phase 4
- Switching From Tenofovir Disoproxi Fumarate to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Antiviral ResistanceStatus unknownNCT03566030
- Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) AdultsStatus unknownNCT02822547Phase 4
- Establishment of Retrospective and Prospective Multicenter Cohort for Chronic Hepatitis BCompletedNCT02263755
- A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination TherapyCompletedNCT02019966
- Antiviral Efficacy of Switching to ETV Plus TDFStatus unknownNCT01597934Phase 4
- Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination TherapyStatus unknownNCT01595633Phase 4
- Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus InfectionStatus unknownNCT01594905Phase 4
- Prospective Observational Cohort Study for the Durability of Anti-viral Therapy in Patients With Chronic Hepatitis BStatus unknownNCT01533051
- A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated InterferonCompletedNCT01531166
- Lamivudine Plus Adefovir Versus Telbivudine Plus Adefovir in Lamivudine Resistant Chronic Hepatitis BStatus unknownNCT01270165Phase 3
- Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease PatientsStatus unknownNCT00823550Phase 4
- Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNACompletedNCT00625560Phase 4
- Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNACompletedNCT00625339Phase 4